Skip to content

Study · Observational study · n = 164 · 2026

5 results

Real-world impact of oral semaglutide on inflammatory markers in patients at high cardiovascular risk.

Mariscal Vázquez S, Jiménez-Méndez C, Pérez Asensio A, Silva E, Rodríguez Delgado P, García Fernández L, Del Rocio Bulo Concellón M, Panera de la Mano JA, Garrido Vital A, Calle Pérez G

Revista clinica espanola28 Apr 2026

PMID42061608 (opens in a new tab)DOI10.1016/j.rceng.2026.502562 (opens in a new tab)PepBankPUB-42061608
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In adults at high cardiovascular risk, hs-CRP fell during oral semaglutide treatment (p < 0.001).

    In plain wordsIn adults at high heart risk, a blood marker of inflammation, hs-CRP, fell during oral semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    Decreasehs-CRP change
    Study

    n = 164

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · oral · 370 days mean follow-upAs given in this study (human).

    Measurements

    hs-CRP
    6.7 mg/L
    baseline
    hs-CRP
    2.9 mg/L
    follow-up

    Source sentences

    Summary
    After a mean follow-up of 370 ± 42 days, hs-CRP decreased from 6.7 ± 9.1 mg/L to 2.9 ± 6.1 mg/L (p < 0.001) and fibrinogen decreased from 428 ± 130 mg/dL to 370 ± 113 mg/dL (p < 0.001).
    2 context sentences
    Summary · context
    This was an observational study that included adult patients receiving treatment with oral semaglutide.
    Summary · context
    A total of 164 patients were included (mean age 68 ± 9 years; 37.6% women).
  2. 02HumanObservational studyEfficacy outcome

    In adults at high cardiovascular risk, fibrinogen fell during oral semaglutide treatment (p < 0.001).

    In plain wordsIn adults at high heart risk, fibrinogen, a blood clotting and inflammation marker, fell during oral semaglutide treatment.

    Peptide
    Semaglutide
    Outcome
    DecreaseFibrinogen change
    Study

    n = 164

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · oral · 370 days mean follow-upAs given in this study (human).

    Measurements

    Fibrinogen
    428 mg/dL
    baseline
    Fibrinogen
    370 mg/dL
    follow-up

    Source sentences

    Summary
    After a mean follow-up of 370 ± 42 days, hs-CRP decreased from 6.7 ± 9.1 mg/L to 2.9 ± 6.1 mg/L (p < 0.001) and fibrinogen decreased from 428 ± 130 mg/dL to 370 ± 113 mg/dL (p < 0.001).
    2 context sentences
    Summary · context
    This was an observational study that included adult patients receiving treatment with oral semaglutide.
    Summary · context
    A total of 164 patients were included (mean age 68 ± 9 years; 37.6% women).
  3. 03HumanObservational studyEfficacy outcome

    In adults at high cardiovascular risk, 60% reached hs-CRP of 2 mg/L or lower on oral semaglutide.

    In plain wordsIn adults at high heart risk, 60% reached a low hs-CRP level of 2 mg/L or lower on oral semaglutide.

    Peptide
    Semaglutide
    Outcome
    Not applicableProportion with hs-CRP of 2 mg/L or lower
    Study

    n = 164

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · oral · 370 days mean follow-upAs given in this study (human).

    Measurements

    Proportion with hs-CRP at or below 2 mg/L
    60%
    follow-up

    Source sentences

    Summary
    Sixty percent (60%) achieved hs-CRP ≤ 2 mg/L
    2 context sentences
    Summary · context
    This was an observational study that included adult patients receiving treatment with oral semaglutide.
    Summary · context
    A total of 164 patients were included (mean age 68 ± 9 years; 37.6% women).
  4. 04HumanObservational studySafety outcome

    In adults at high cardiovascular risk, oral semaglutide had a favorable safety profile; no event rates were reported.

    In plain wordsIn adults at high heart risk, oral semaglutide was reported to have a favorable safety profile.

    Peptide
    Semaglutide
    Outcome
    Not applicableSafety profile
    Study

    n = 164

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · oral · 370 days mean follow-upAs given in this study (human).

    Source sentences

    Summary
    Sixty percent (60%) achieved hs-CRP ≤ 2 mg/L, with a favorable safety profile.
    2 context sentences
    Summary · context
    This was an observational study that included adult patients receiving treatment with oral semaglutide.
    Summary · context
    A total of 164 patients were included (mean age 68 ± 9 years; 37.6% women).
  5. 05HumanObservational studyOther

    In adults at high cardiovascular risk, baseline hs-CRP and continuity of semaglutide treatment were independent predictors of reaching hs-CRP of 2 mg/L or lower.

    In plain wordsIn adults at high heart risk, higher starting hs-CRP and staying on semaglutide predicted reaching a low hs-CRP level.

    Peptide
    Semaglutide
    Outcome
    Not applicablePredictors of sustained hs-CRP response
    Study

    n = 164

    Outcome group
    Inflammation markers · Immune and inflammation
    Studied dose
    Dose not stated · oral · 370 days mean follow-upAs given in this study (human).

    Source sentences

    Summary
    In multivariate analysis, baseline hs-CRP and continuity of semaglutide treatment emerged as independent predictors of hs-CRP ≤ 2 mg/L.
    2 context sentences
    Summary · context
    This was an observational study that included adult patients receiving treatment with oral semaglutide.
    Summary · context
    A total of 164 patients were included (mean age 68 ± 9 years; 37.6% women).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.